Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.…
Tectonic Therapeutic to Participate in Upcoming Investor Conferences
Tectonic Therapeutic (NASDAQ: TECX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 60 employees.
The shares were at 20.73 USD on 20 November 2026, up 9.2% over 52 weeks. Its 52-week range is 16.77 USD to 39.53 USD: the price is 47.6% below the high and 23.6% above the low.
Its market capitalisation is 405.26M USD.
Tectonic Therapeutic reports return on equity of -29.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 230.75M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 71.00 USD is 242.5% above the current price. The next earnings report is expected on 25 February 2027.